Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer

The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell lung cancer (NSCLC) and resulted in the drug’s approval for this indication. A cohort that included neoadjuvant and adjuvan...

Full description

Bibliographic Details
Main Authors: Jonathan W. Goldman, Lynette M. Sholl, Sanja Dacic, Michael C. Fishbein, Yonina R. Murciano-Goroff, Ravi Rajaram, Sylwia Szymczak, Anna M. Szpurka, Bo H. Chao, Alexander Drilon
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
RET fusion
selective RET inhibitor
NSCLC
neoadjuvant
major pathologic response
pathologic complete response
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1178313/full

Similar Items

Similar Items